



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, India.
Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Date: 12th November 2021

To
National Stock Exchange of India Limited &
BSE Limited.
Scrip Code: NSE- GRANULES; BSE-532482.

Sub: Outcome of 207th Board meeting dated 12th November 2021.
Ref: Regulation 30 and 33 of the Listing Regulations.

Dear Sir,

The Board of Directors at their meeting has -

1. Approved the Un-Audited financial results (Standalone & Consolidated) for the second quarter ended September 30, 2021, prepared under Indian Accounting Standards (Ind - AS).
2. Declared second interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% of paid-up capital for the financial year 2021-22.
3. Fixed the record date as November 25, 2021, for the purpose of payment of second interim dividend for the financial year 2021-22.

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing the Un-Audited financial results (Standalone and Consolidated) of the Company for the second quarter ended September 30, 2021.

We also enclose a copy of the Limited Review Report of the Statutory Auditors of the Company, as required under Regulation 33 of the Listing Regulations and press release.


The meeting of the Board of Directors of the Company commenced at 10.00 A.M and concluded at 05.00 P.M.

Request you to take the above information on record.

Thanking You.
Yours faithfully,

For GRANULES INDIA LIMITED

G. Chaitanya
CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)



Encl: As above

B S R & Associates LLP

Chartered Accountants

Salarpuriya Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results under Regulation 33 of the Listing Regulations

To
Board of Directors of Granules India Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Granules India Limited (“the Company”) for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 (“the statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**
Chartered Accountants
(Firm's Registration No. 116231W/W-100024)

SRIRAM
MAHALINGAM
Digitally signed by
SRIRAM MAHALINGAM
Date: 2021.11.12
16:04:31 +05'30'

Sriram Mahalingam
Partner
Membership No.: 049642
UDIN: 21049642AAAAFA5707

Place: Palakkad, Kerala
Date: 12 November 2021

Registered Office:



Statement of Standalone Unaudited Results for the quarter and half year ended September 30, 2021

Sl No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
	Income						
1	Revenue from operations	70,369.40	73,211.59	83,449.84	143,580.99	157,742.00	313,498.24
2	Other income	428.32	735.57	306.91	916.94	771.30	1,372.32
3	Total income (1+2)	70,797.72	73,947.16	83,756.75	144,497.93	158,513.30	314,870.56
4	Expenses						
	(a) Cost of materials consumed	41,481.92	43,251.32	39,832.77	84,733.24	75,812.29	150,219.35
	(b) Changes in inventories of work in progress and finished goods	(2,128.56)	(4,158.13)	868.01	(6,286.68)	(1,062.62)	744.93
	(c) Employee benefits expense	6,429.44	7,121.46	8,312.81	13,550.90	16,508.33	31,825.23
	(d) Finance costs	401.17	538.38	623.12	939.55	1,207.91	2,377.39
	(e) Depreciation and amortisation expense	3,185.57	3,149.57	2,959.05	6,335.14	5,816.99	11,845.14
	(f) Other expenses	15,245.30	11,993.40	10,458.35	26,991.75	22,775.02	44,571.50
	Total expenses	64,614.84	61,896.00	63,054.11	126,263.90	121,057.92	241,583.54
5	Profit before tax (3-4)	6,182.88	12,051.16	20,702.64	18,234.03	37,455.38	73,287.02
6	Tax expense						
	a) Current tax	1,600.55	3,119.66	5,456.29	4,720.21	11,180.30	20,231.19
	b) Deferred tax	(27.23)	(53.07)	(200.97)	(80.30)	(1,672.34)	(1,697.38)
	c) Adjustment of tax relating to earlier periods	-	-	-	-	-	(525.10)
	Total tax expense	1,573.32	3,066.59	5,255.32	4,639.91	9,507.96	18,008.71
7	Profit for the period (5-6)	4,609.56	8,984.57	15,447.32	13,594.12	27,947.42	55,278.31
8	Other comprehensive income (net of tax)						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	(36.69)
	(ii) income tax on (i) above	-	-	-	-	-	9.23
	(b) (i) items that will be reclassified to profit or loss	1,769.84	(1,081.05)	(640.52)	688.79	(1,614.28)	(699.98)
	(ii) income tax on (i) above	(445.43)	272.08	161.21	(173.35)	406.29	176.17
	Total other comprehensive income, net of tax	1,324.41	(808.97)	(479.31)	515.44	(1,207.99)	(551.27)
9	Total comprehensive income (7+8)	5,933.97	8,175.60	14,968.01	14,109.56	26,739.43	54,727.04
10	Paid-up equity share capital (Face Value of Rs.1/- per share)	2,476.75	2,476.75	2,476.41	2,476.75	2,476.41	2,476.75
11	Other equity						213,785.42
12	Earnings per share (Face value Rs. 1/- each)						
	(a) Basic (in Rs.)	1.86	3.63	6.24	5.49	11.15	22.18
	(b) Diluted (in Rs.)	1.85	3.61	6.21	5.46	11.08	22.09
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)



Standalone statement of Assets and Liabilities :		Rs in lakhs	
Sl. No.	Particulars	As at	As at
		September 30, 2021	March 31, 2021
		Un-Audited	Audited
I	ASSETS		
	Non-current assets		
	a) Property, plant and equipment	92,873.87	91,690.72
	b) Right-of-use assets	974.27	939.93
	c) Capital work-in-progress	28,243.65	14,658.41
	d) Other intangible assets	6,408.97	5,869.36
	e) Intangible assets under development	1,580.87	1,742.77
	f) Financial assets		
	i) Investments	59,653.12	59,153.12
	ii) Loans	1,119.77	1,011.21
	iii) Others	1,216.45	1,191.08
	g) Other non-current assets	5,421.79	4,240.01
	Total non-current assets	197,492.76	180,496.61
	Current assets		
	a) Inventories	53,207.04	46,169.68
	b) Financial assets		
	i) Trade receivables	99,196.39	101,423.62
	ii) Cash and cash equivalents	7,381.87	2,003.29
	iii) Bank balances other than cash and cash equivalents above	27,039.69	22,119.38
	iv) Loans	31.50	27.71
	v) Other financial assets	136.63	38.17
	c) Other current assets	14,924.07	16,004.89
	Total current assets	201,917.19	187,786.74
	TOTAL ASSETS	399,409.95	368,283.35
II	EQUITY AND LIABILITIES		
	Equity		
	a) Equity share capital	2,476.75	2,476.75
	b) Other equity	225,798.80	213,785.42
	Total equity	228,275.55	216,262.17
	Liabilities		
	Non-current liabilities		
	a) Financial liabilities		
	i) Borrowings	28,600.28	33,380.74
	ii) Lease liabilities	674.35	733.59
	b) Provisions	2,941.38	2,484.22
	c) Deferred tax liabilities (net)	2,682.38	2,589.32
	Total non-current liabilities	34,898.39	39,187.87
	Current liabilities		
	a) Financial liabilities		
	i) Borrowings	67,834.01	50,464.40
	ii) Lease liabilities	388.91	283.45
	iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises	1,035.60	324.69
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	54,749.06	50,440.47
	iv) Other financial liabilities	9,752.25	7,213.87
	b) Other current liabilities	1,702.16	1,966.85
	c) Provisions	682.13	682.13
	d) Current tax liabilities (net)	91.89	1,457.45
	Total current liabilities	136,236.01	112,833.31
	Total liabilities	171,134.40	152,021.18
	TOTAL EQUITY AND LIABILITIES	399,409.95	368,283.35




Statement of standalone cash flow :	Rs in lakhs		
	For the half year ended September 30, 2021	For the half year ended September 30, 2020	For the year ended March 31, 2021
	Un-Audited	Un-Audited	Audited
Cash flow from operating activities			
Profit before tax	18,234.03	37,455.38	73,287.02
<i>Adjustments to reconcile profit before tax to net cash flows</i>			
Depreciation and amortisation expense	6,335.14	5,816.99	11,845.14
Bad debts written off	-	-	162.22
Allowance for doubtful trade receivables	523.88	921.24	749.95
Allowance for doubtful advances	-	-	169.53
Loss on sale of fixed assets (net)	436.66	0.01	36.84
Changes in fair value of cashflow hedges	674.08	461.52	1,204.52
Net loss/(gain) on foreign exchange fluctuations (unrealised)	(275.22)	2,014.94	(0.77)
Share based compensation expense	59.54	50.00	151.24
Interest expense	939.55	1,207.91	2,377.39
Interest income	(573.25)	(760.16)	(1,323.98)
Operating profit before working capital changes	26,354.41	47,167.83	88,659.10
<i>Movements in working capital:</i>			
Decrease/(increase) in trade receivables	3,151.68	(38,272.68)	(38,613.01)
Increase in inventories	(7,037.36)	(5,673.20)	(11,774.94)
Decrease/(increase) in other assets	1,051.66	(1,199.07)	(4,335.91)
Increase in trade payables, other liabilities and provisions	3,442.60	22,574.95	22,124.71
Cash generated from operations	26,962.99	24,597.83	56,059.95
Taxes paid (net of refunds)	(6,085.77)	(7,665.91)	(18,594.11)
Net cash generated from operating activities	(A) 20,877.22	16,931.92	37,465.84
Cash flow from investing activities			
Purchase of fixed assets including capital work-in-progress, capital advances and payables for capital goods	(18,815.71)	(7,497.09)	(22,262.59)
Proceeds from sale of fixed assets	21.29	0.11	32.71
Placement of bank deposits	(4,923.32)	6,163.55	(12,317.76)
Purchase of investments	-	(20.00)	(20.00)
Investment in subsidiaries	(500.00)	-	(2,500.00)
Proceeds from sale of associate	-	10,985.24	10,985.24
Loans given to subsidiaries	(102.48)	-	(77.51)
Interest received	573.00	500.57	2,898.04
Net cash used in investing Activities	(B) (23,747.22)	10,132.38	(23,261.87)
Cash flow from financing activities			
Proceeds from issuance of shares	321.05	381.52	414.50
Repayment of borrowings	(4,887.38)	(5,197.26)	(10,153.55)
Proceeds of short-term borrowings, net	16,498.81	272.32	2,960.23
Repayment of lease liability (including related interest)	(206.35)	(109.69)	(271.79)
Payment towards Buyback including transaction cost	-	(17,714.41)	(17,714.41)
Interest paid	(1,078.31)	(1,177.68)	(2,383.78)
Dividend paid on equity shares including tax thereon	(2,477.10)	(1,236.48)	(2,472.08)
Net cash used in financing activities	(C) 8,170.72	(24,781.68)	(29,620.88)
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 5,300.72	2,282.62	(15,416.91)
Effect of exchange differences on translation of foreign currency cash and cash equivalents	77.86	(21.31)	(12.27)
Cash and cash equivalents at the beginning of the period	2,003.29	17,432.47	17,432.47
Cash and cash equivalents at the end of the period	7,381.87	19,693.78	2,003.29

Note: The above Statement of Cash flow has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'

Notes:

- The above standalone un-audited financial results for the quarter and half-year ended September 30, 2021 have been reviewed by the Audit Committee on November 12, 2021 and approved by the Board of Directors at their meeting held on November 12, 2021.
- The standalone un-audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and half-year ended September 30, 2021.
- As the out-break continues to evolve, the company will continue to closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Company, there is no significant / material impact of COVID-19 on the results for the quarter and half-year ended September 30, 2021 and year ended March 31, 2021.
- The Company operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- The Board of Directors at their meeting held on November 12, 2021 has declared second interim dividend of 25 paise per equity share of Re.1/- each.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- On March 24, 2021, the Ministry of Corporate Affairs (MCA) through notification, amended Schedule III to the Companies Act, 2013, applicable for financial period commencing from April 01, 2021. The Company has incorporated the changes as per the said amendment in the above results and has also changed comparative numbers wherever it is applicable.
- The figures for the corresponding previous periods have been reclassified/regrouped wherever necessary, to make them comparable.

for and on behalf of the Board


Dr. Krishna Prasad Chigurupati
 Chairman and Managing Director



Place : Hyderabad
 Date : November 12, 2021

B S R & Associates LLP

Chartered Accountants

Salarpuriya Knowledge City,
Orwell, B Wing, 6th Floor, Unit-3,
Sy No. 83/1, Plot No. 02, Raidurg,
Hyderabad – 500 081 - India

Telephone: +91 40 7182 2000
Fax: +91 40 7182 2399

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results under Regulation 33 of the Listing Regulations

To
Board of Directors of Granules India Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Granules India Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2021 and year to date results for the period from 1 April 2021 to 30 September 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulations’).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Granules USA Inc.	Wholly owned subsidiary
Granules Pharmaceutical Inc.	Wholly owned subsidiary
Granules Europe Limited	Wholly owned subsidiary
Granules Life Sciences Private Limited	Wholly owned subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

Limited review report (unmodified) on unaudited quarterly consolidated financial results and consolidated year-to-date results of Granules India Limited under Regulation 33 of the Listing Regulations

6. We did not review the interim financial results of two subsidiaries included in the Statement, whose interim financial results reflect total assets of Rs 120,035.51 lakhs as at 30 September 2021 and total revenues of Rs 36,853.74 lakhs and Rs 69,934.75 lakhs, total net profit after tax of Rs 1,856.86 lakhs and Rs 3,731.86 lakhs and total comprehensive income of Rs 1,726.65 lakhs and Rs 4,702.71 lakhs, for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021, respectively, and cash outflows (net) of Rs. 724.50 for the period from 1 April 2021 to 30 September 2021, as considered in the consolidated unaudited financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

7. The Statement includes the interim financial information of two subsidiaries which have not been reviewed, whose interim financial results reflect total assets of Rs. 2,990.36 as at 30 September 2021 and total revenue of Rs Nil and Rs Nil, total net loss after tax of Rs 45.30 lakhs and Rs 85.36 lakhs and total comprehensive loss of Rs 16.78 lakhs and Rs 72.85 lakhs for the quarter ended 30 September 2021 and for the period from 1 April 2021 to 30 September 2021, respectively, and cash outflows (net) of Rs. 417.89 for the period from 1 April 2021 to 30 September 2021, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration No.: 116231W/ W-100024

SRIRAM

MAHALINGAM

Digitally signed by
SRIRAM MAHALINGAM
Date: 2021.11.12
16:06:21 +05'30'

Sriram Mahalingam

Partner

Membership No.: 049642

UDIN: 21049642AAAAFB6207

Place: Palakkad, Kerala

Date: 12 November 2021



GRANULES INDIA LIMITED
 Regd Office : 2nd Floor, 3rd Block, My Home Hub
 Madhapur, Hyderabad 500 081
 CIN:L24110TG1991PLC012471

Rs in lakhs

Statement of Consolidated Unaudited Results for the quarter and half year ended September 30, 2021

Sl No.	Particulars	Quarter ended			Half yearly ended		Year ended
		30.09.2021 Un-Audited	30.06.2021 Un-Audited	30.09.2020 Un-Audited	30.09.2021 Un-Audited	30.09.2020 Un-Audited	31.03.2021 Audited
	Income						
1	Revenue from operations	88,833.09	84,984.66	85,812.18	173,817.75	159,371.80	323,754.28
2	Other income	435.21	762.07	322.26	950.33	719.05	2,688.18
3	Total income (1+2)	89,268.30	85,746.73	86,134.44	174,768.08	160,090.85	326,442.46
4	Expenses						
	(a) Cost of materials consumed	46,046.20	46,006.37	41,801.81	92,052.57	79,161.97	159,027.67
	(b) Changes in inventories of work in progress and finished goods	(2,387.48)	(7,099.07)	(5,690.28)	(9,486.55)	(13,291.34)	(19,900.33)
	(c) Employee benefits expense	9,251.61	9,538.96	10,454.18	18,790.57	20,734.09	40,818.10
	(d) Finance costs	546.30	679.32	626.93	1,225.62	1,222.19	2,628.41
	(e) Depreciation and amortisation expense	3,984.09	3,938.14	3,606.09	7,922.23	7,013.83	15,146.25
	(f) Other expenses	20,804.67	16,395.79	13,605.46	36,953.51	28,600.97	58,285.93
	Total expenses	78,245.39	69,459.51	64,404.19	147,457.95	123,441.71	256,006.03
5	Profit before tax (3-4)	11,022.91	16,287.22	21,730.25	27,310.13	36,649.14	70,436.43
6	Tax expense						
	a) Current tax	1,840.65	3,453.88	6,141.76	5,294.53	12,098.61	20,255.74
	b) Deferred tax	1,114.39	813.15	(774.90)	1,927.54	(2,957.79)	(4,046.68)
	c) Adjustment of tax relating to earlier periods	-	-	-	-	-	(718.53)
	Total tax expense	2,955.04	4,267.03	5,366.86	7,222.07	9,140.82	15,490.53
7	Profit for the period (5-6)	8,067.87	12,020.19	16,363.39	20,088.06	27,508.32	54,945.90
8	Other comprehensive income (net of tax)						
	(a) (i) items that will not be reclassified to profit or loss	-	-	-	-	-	(36.69)
	(ii) income tax on (i) above	-	-	-	-	-	9.23
	(b) (i) items that will be reclassified to profit or loss	1,668.15	4.00	(2,156.35)	1,672.15	(3,034.59)	(2,764.76)
	(ii) income tax on (i) above	(445.43)	272.08	161.21	(173.35)	406.29	176.17
	Total other comprehensive income, net of tax	1,222.72	276.08	(1,995.14)	1,498.80	(2,628.30)	(2,616.05)
9	Total comprehensive income (7+8)	9,290.59	12,296.27	14,368.25	21,586.86	24,880.02	52,329.85
10	Paid-up equity share capital (Face Value of Rs.1/- per share)	2,476.75	2,476.75	2,476.41	2,476.75	2,476.41	2,476.75
11	Other equity						214,850.68
12	Earnings per share (Face value Rs. 1/- each)						
	(a) Basic (in Rs.)	3.26	4.85	6.60	8.11	10.97	22.05
	(b) Diluted (in Rs.)	3.24	4.83	6.56	8.07	10.91	21.95
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)



Consolidated Statement of Assets and Liabilities :		Rs in lakhs	
Sl.No.	Particulars	As at	
		September 30, 2021 Un-Audited	March 31, 2021 Audited
I	ASSETS		
	Non-current assets		
	a) Property, plant and equipment	109,685.50	106,126.47
	b) Right-of-use assets	1,002.53	995.68
	c) Capital work-in-progress	34,453.02	18,477.17
	d) Other intangible assets	25,912.27	26,077.42
	e) Intangible assets under development	5,070.59	5,431.00
	f) Financial assets		
	i) Investments	1,924.29	1,898.94
	ii) Loans	-	95.19
	iii) Others	1,243.96	1,218.22
	g) Deferred tax assets	149.80	77.32
	h) Income tax assets (net)	601.65	568.46
	i) Other non-current assets	11,411.61	10,679.00
	Total non-current assets	191,455.22	171,644.87
	Current assets		
	a) Inventories	89,384.76	78,217.85
	b) Financial assets		
	i) Trade receivables	78,604.92	76,542.01
	ii) Cash and cash equivalents	8,419.79	4,183.59
	iii) Bank balances other than cash and cash equivalents above	27,439.54	22,920.80
	iv) Loans	1,029.33	999.34
	v) Other financial assets	171.55	56.95
	c) Other current assets	15,486.90	16,779.63
	Total current assets	220,536.79	199,700.17
	TOTAL ASSETS	411,992.01	371,345.04
II	EQUITY AND LIABILITIES		
	Equity		
	a) Equity share capital	2,476.75	2,476.75
	b) Other equity	233,623.56	214,850.68
	Total equity	236,100.31	217,327.43
	Liabilities		
	Non-current liabilities		
	a) Financial liabilities		
	i) Borrowings	28,600.28	33,380.74
	ii) Lease liabilities	674.35	733.59
	b) Provisions	2,941.38	2,484.22
	c) Deferred tax liabilities (net)	2,300.86	109.25
	Total non-current liabilities	34,516.87	36,707.80
	Current liabilities		
	a) Financial liabilities		
	i) Borrowings	67,834.01	50,464.40
	ii) Lease liabilities	419.10	342.25
	iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises	1,035.60	324.69
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	57,894.53	53,780.06
	iv) Other financial liabilities	11,010.76	8,178.82
	b) Other current liabilities	1,771.40	2,018.68
	c) Provisions	682.13	682.13
	d) Current tax liabilities (net)	727.30	1,518.78
	Total current liabilities	141,374.83	117,309.81
	Total liabilities	175,891.70	154,017.61
	TOTAL EQUITY AND LIABILITIES	411,992.01	371,345.04



Statement of Consolidated cash flow :	For the half year	For the half year	For the year ended
	ended September	ended September	March 31, 2021
	30, 2021	30, 2020	
	Un-Audited	Un-Audited	Audited
Cash flow from operating activities			
Profit before tax	27,310.13	36,649.14	70,436.43
<i>Adjustments to reconcile profit before tax to net cash flows</i>			
Depreciation and amortisation expense	7,922.23	7,013.83	15,146.25
Bad debts written off	-	16.80	246.31
Allowance for doubtful trade receivables	523.88	921.24	749.95
Allowance for doubtful advances	-	-	169.53
Loss on sale of fixed assets (net)	436.66	0.01	39.19
Changes in fair value of cashflow hedges	674.08	461.52	1,204.52
Net loss/(gain) on foreign exchange fluctuations (unrealised)	(276.13)	2,029.65	23.56
Write off of Intangible assets under development	-	-	72.89
Share based payment expense	59.54	97.12	399.86
Interest expense	1,225.61	1,222.19	2,628.40
Interest income	(604.28)	(645.63)	(1,237.87)
Operating profit before working capital changes	37,271.72	47,765.87	89,879.02
<i>Movements in working capital:</i>			
Increase in trade receivables	(1,000.12)	(15,827.51)	(3,639.03)
Increase in inventories	(10,643.45)	(18,424.57)	(34,588.76)
Decrease/(increase) in other assets	1,347.78	(1,143.73)	(4,550.37)
Increase in trade payables, other liabilities and provisions	2,460.63	14,917.13	15,283.61
Cash generated from operations	29,436.56	27,287.19	62,384.47
Taxes paid (net of refunds)	(6,100.97)	(7,847.98)	(19,136.69)
Net cash generated from operating activities	(A) 23,335.59	19,439.21	43,247.78
Cash flow from investing activities			
Purchase of fixed assets including capital work-in-progress, capital advances and payables for capital goods	(23,140.21)	(10,482.44)	(27,134.16)
Proceeds from sale of fixed assets	21.29	0.11	32.71
Placement of bank deposits	(4,521.75)	6,163.55	(13,119.18)
Purchase of investments	-	(20.00)	(20.00)
Proceeds from sale of associate	-	10,985.24	10,985.24
Interest received	607.39	616.05	1,541.89
Net cash used in investing activities	(B) (27,033.28)	7,262.51	(27,713.50)
Cash flow from financing activities			
Proceeds from issuance of shares	321.05	381.52	414.50
Repayment of borrowings	(4,887.38)	(5,197.26)	(10,153.55)
Proceeds of short-term borrowings, net	16,498.81	1,608.72	2,960.23
Repayment of lease liability (including related interest)	(242.16)	(147.23)	(338.40)
Payment towards Buyback including transaction cost	-	(17,714.41)	(17,714.41)
Interest paid	(1,357.19)	(1,184.76)	(2,627.60)
Dividend paid on equity shares including tax thereon	(2,477.10)	(1,236.48)	(2,472.08)
Net cash used in financing activities	(C) 7,856.03	(23,489.90)	(29,931.31)
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 4,158.34	3,211.82	(14,397.03)
Effect of exchange differences on translation of foreign currency cash and cash equivalents	77.86	(21.31)	(12.27)
Cash and cash equivalents at the beginning of the period	4,183.59	18,592.89	18,592.89
Cash and cash equivalents at the end of the period	8,419.79	21,783.40	4,183.59

Note: The above Statement of Cash flow has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'

Notes:

- The above consolidated un-audited financial results for the quarter and half year ended September 30, 2021 have been reviewed by the Audit Committee on November 12, 2021 and approved by the Board of Directors at their meeting held on November 12, 2021.
- The consolidated un-audited financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Auditors of the Company have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2021.
- The subsidiaries considered for the consolidated financial statements for the quarter and half-year ended September 30, 2021 are Granules USA Inc., Granules Pharmaceuticals Inc., Granules Europe Limited and Granules Life Sciences Private Limited (together known as "Subsidiaries").
- The Group operates in one reportable business segment of Pharmaceutical products including ingredients and intermediaries.
- As the out-break continues to evolve, the company will continue to closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Company, there is no significant / material impact of COVID-19 on the results for the quarter and half-year ended September 30, 2021 and year ended March 31, 2021.
- The Board of Directors at their meeting held on November 12, 2021 has declared second interim dividend of 25 paise per equity share of Re.1/- each.
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the code will come into effect has not been notified. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- On March 24, 2021, the Ministry of Corporate Affairs (MCA) through notification, amended Schedule III to the Companies Act, 2013, applicable for financial period commencing from April 01, 2021. The Group has incorporated the changes as per the said amendment in the above results and has also changed comparative numbers wherever it is applicable.
- The figures for the corresponding previous periods have been reclassified/regrouped wherever necessary, to make them comparable.
- Standalone results for the quarter / year ended are as under -

Particulars	Rs in lakhs					
	Quarter ended			Half- Year ended		Year ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
Revenue from Operations	70,369.40	73,211.59	83,449.84	143,580.99	157,742.00	313,498.24
Profit Before Tax	6,182.88	12,051.16	20,702.64	18,234.03	37,455.38	73,287.02
Profit After Tax	4,609.56	8,984.57	15,447.32	13,594.12	27,947.42	55,278.31

Place : Hyderabad
Date : November 12, 2021



for and on behalf of the Board
[Signature]
Dr. Krishna Prasad Chigurupati
Chairman and Managing Director



Press Release

For Immediate Release

**Granules India reports Income from operations at INR 888 Cr up 4% YoY,
EBITDA at INR 151 Cr, EBITDA Margin at 17%
PAT at INR 81 Cr, down 51% YoY**

Hyderabad, 12th November 2021: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and half-year ended September 30, 2021.

Q2FY22 Financial Highlights (All numbers in INR Cr except Margins)

CONSOLIDATED FINANCIALS	Q2FY22	Q2FY21	Growth (YoY)
Income from Operations	888	858	4%
Operating Profit	151	256	(41%)
Operating Profit Margin	17%	30%	
PAT	81	164	(51%)
Net Profit Margin	9%	19%	

Financial and Business Highlights for Q2FY22

- Granules Q2 business was unfavourably impacted due to difficulties in procuring Raw materials, mainly from China due to Chinese dual energy policy and increased procurement prices for almost all items due to interruptions in supply of materials and increased logistics costs arising out of vessel shortage and port congestion in various part of the world
- Q2FY22 revenues at INR 888 Crs, growth of 4% YoY. EBITDA stood at INR 151 Crs, down by 41% YoY. EBITDA margins stood at 17% compared to 30%. PAT at INR 81 Crs, down by 51%
- Gross margin % drop from 57.9% to 50.9% was on account of reduction in margins of all major products especially Paracetamol due to increase in KSM prices and increased logistics cost. Price pressure in USA has also resulted in marginal drop in Gross margin for Core products. The entire loss of Gross margin for the current quarter was mainly absorbed by Granules. We expect to pass on some of the increases to our customers from Q3FY22 onwards.
- Pharmaceutical Formulation Intermediates (PFI) segment grew 10% YoY, Finished Dosage (FD) grew 18% YoY and, Active Pharmaceutical Ingredients (API) segment down by 25% YoY mainly due to Paracetamol KSM supply disruption.

- During the quarter:
 - Revenue share from other molecules has increased to 19% and Revenue share of FD has increased to 57% consistent with our strategy
 - We filed one ANDA, one European Dossier, one US DMF and one CEP.
 - R&D expenses has significantly gone up in line with our accelerated R&D strategy.
- The Board of Directors has declared its second interim dividend of 25 paise per equity share of INR 1/- each.

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “The last quarter was one of the most challenging quarters that we have witnessed in the recent past. We were unable to pass on our cost increases to our customers.

Based on ongoing discussions with customers, we are confident of passing on our price increases substantially from Q3FY22 onwards. We expect that our gross margins will see a recovery and we believe that our performance for the rest of the fiscal will be substantially better.

We have been taking all necessary measures to de-risk ourselves from supply chain disruptions and expect to see these efforts bear fruits next fiscal onwards.

Due to the current volatile and uncertain environment, we believe that we will not be able to meet our guidance, and it will not be prudent on our part to give any future guidance until the situation becomes stable. All our projects and plans are on track, and I am very confident that the current fiscal will be a one off and not affect our long-term growth strategy and aspirations.”

Segmental, Molecule and Geographical Mix for Q2 FY22 (All numbers in INR Cr)

Segmental Mix	Q2FY22	Q2FY21
FD	507	430
PFI	191	173
API	190	255

Geographical Mix	Q2FY22	Q2FY21
North America	508	472
Europe	182	154
Latin America	63	66
India	98	118
ROW	37	48

Molecule Mix %	Q2FY22	Q2FY21
Paracetamol	33%	33%
Metformin	28%	27%
Ibuprofen	14%	17%
Guaifenesin	2%	5%
Methocarbamol	4%	2%
Others	19%	16%

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best in class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 75+ countries with offices across India, US and UK The Company has 7 manufacturing facilities out of which 6 are located in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Contacts:

Krishna Raghunathan
 VP – Finance and Investor Relations
 040-69043573
krishna.raghunathan@granulesindia.com

Chaitanya Tummala
 Company Secretary
 040-69043614
chaitanya.tummala@granulesindia.com

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.